Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

RFN for SIJ Disease Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by Barts & The London NHS Trust
Sponsor:
Information provided by (Responsible Party):
Barts & The London NHS Trust
ClinicalTrials.gov Identifier:
NCT01726608
First received: November 11, 2012
Last updated: January 28, 2013
Last verified: January 2013

November 11, 2012
January 28, 2013
November 2012
December 2013   (final data collection date for primary outcome measure)
Pain Intensity [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01726608 on ClinicalTrials.gov Archive Site
  • Pain Intensity [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Quality of pain [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
    Short Form Mcgill Pain Questionnaire
  • Health related Quality of life [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
    Short form health survey
  • Anxiety and Depression [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
    Hospital and Depression Scale
  • Functional Disability [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
    Oswestry Low Back Pain Disability Questionnaire
  • Health related quality of life and quality-adjusted life years [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
    Euro Quol EQ-5D scale
  • Portion of patients randomised to sham requiring rescue therapy with RFN [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
RFN for SIJ Disease Study
A Sham, Controlled, Randomised Trial to Investigate the Effects of Radiofrequency Neurotomy Using Simplicity III® on Patients With Sacroiliac Joint Pain.

The purpose of the study is to investigate if a technique called Simplicity III® Radiofrequency Neurotomy is effective in improving the management of sacroiliac joint pain. Currently there are a variety of treatments for managing this pain but there is still some doubt as to which treatments are the most effective. Simplicity III® is one such treatment for sacroiliac joint pain and has been used in the NHS for many years. It uses electrical current to generate heat around the tip of the needle placed close to the nerves that supply the sacro-iliac joint. This heat ablates the specific nerves supplying the joint and improves pain.

The traditional method used to treat this type of pain uses multiple injections to target the nerves supplying the joint. This method is however both time consuming and the results are variable depending upon the number of injections. Therefore a new electrode, called the Simplicity III®, was developed to allow the treatment to be undertaken using fewer injections. Although this treatment has received formal approval, undergone conformity assessment and is available in certain specialist NHS centres for clinical use, there is presently limited evidence with regards to its clinical efficacy. We wish to test the effectiveness of this new device in treating sacroiliac joint pain. The best way to prove the clinical effectiveness is to compare Simplicity III® against an identical procedure where the electrode is not switched on and neither the patient nor the doctor is aware whether it was switched on. Once pain has been assessed at 3 months, those patients not receiving active treatment and remaining in pain will be offered the active treatment.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Sacro Iliac Joint Pain
Procedure: Comparison of active versus sham radiofrequency neurotomy with Simplicity III
  • Active Comparator: Radiofrequency neurotomy
    Active Radiofrequency Neurotomy
    Intervention: Procedure: Comparison of active versus sham radiofrequency neurotomy with Simplicity III
  • Placebo Comparator: Sham
    Sham radiofrequency neurotomy
    Intervention: Procedure: Comparison of active versus sham radiofrequency neurotomy with Simplicity III
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
Not Provided
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Written, informed consent
  2. Age: 18 - 80 years old
  3. Low back pain of more than 6 months duration with a minimum pain intensity of greater than 5 out of 10 on an 11-point numerical rating scale in the 7 days preceding study entry.
  4. Subjects must achieve greater than 80% reduction in pain following each diagnostic, intra-articular block. Subjects must undergo 2 blocks in total prior to randomisation.
  5. Female subjects of potential childbearing age must be using adequate contraception (i.e. using oral or intramuscular contraception or an IUCD) and must have a negative urine test.
  6. No vulnerable patient groups shall be recruited into this study

Exclusion Criteria:

  1. Subjects who do not fulfill inclusion criteria
  2. Subjects who have previously been treated by any sacroiliac joint radiofrequency neurotomy
  3. Subjects who are breastfeeding
  4. Contraindications to local anaesthetics and radiofrequency neurotomy as listed in their respective summary of product characteristics
  5. Subjects with documented or suspected alcohol or drug abuse, or who are suspected of having an addictive personality
  6. Subjects to whom any of the following apply: Major trauma to the lumbar spine in the six months preceding study entry. Infection in the lumbar spine in the six months preceding study entry
  7. Subjects' known to have a condition that, in the investigator's judgment precludes entry into the study.
  8. Subjects with a significant psychiatric disorder (including depression) or subjects receiving anti-psychotic medication.
  9. Subjects who have received an investigational drug or have used an investigational device in the 30 days preceding study entry.
  10. Subjects unable to comply with the study assessments or unable to complete the questionnaires.
Both
18 Years to 80 Years
No
Contact: Vivek Mehta, MD FRCA +442034655361 vivek.mehta@bartshealth.nhs.uk
Contact: Sibtain Anwar, MA MB FRCA +442034655361 sibtain.anwar@bartshealth.nhs.uk
United Kingdom
 
NCT01726608
Reda 7869
Yes
Barts & The London NHS Trust
Barts & The London NHS Trust
Not Provided
Principal Investigator: Vivek Mehta, MD FRCA Barts & The London NHS Trust
Study Director: Sibtain Anwar, MA MB FRCA Barts & The London NHS Trust
Barts & The London NHS Trust
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP